Home > Healthcare > Analytical Instruments > Molecular Analysis > Molecular Cytogenetics Market

Molecular Cytogenetics Market Trends

Report ID: GMI8693
Published Date: Mar 2024
Report Format: PDF

Download Free Sample

Molecular Cytogenetics Market Trends

Technological advancements like automation, high-throughput sequencing, and bioinformatics have transformed molecular cytogenetics, boosting sensitivity, specificity, and throughput. These improvements have yielded more efficient, accurate, and cost-effective assays, enabling comprehensive genomic analyses and faster identification of genetic abnormalities. This has spurred the adoption of molecular cytogenetics in research and clinical settings.

Molecular cytogenetics techniques have broad applications in both research and clinical diagnostics, spanning from basic genetic research to advanced clinical testing. Their expanding use drives increased demand and adoption.
In research, these techniques facilitate the study of chromosomal structure, function, and dynamics, advancing the understanding of genetics and genomics. In clinical diagnostics, they enable accurate diagnosis, prognosis, and monitoring of genetic disorders, cancer, and other diseases, leading to their integration into routine clinical practice.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

The global molecular cytogenetics industry was valued at around USD 2.5 billion in 2023 and is estimated to reach over USD 5.9 billion by 2032, owing to a significant increase in the prevalence of genetic disorders and cancer globally, fueled by factors such as aging populations, lifestyle changes, and environmental factors.

The comparative genomic hybridization (CGH) segment held a substantial revenue share worth USD 978.3 million in 2023, owing to its ability to detect chromosomal imbalances and copy number variations across the entire genome, with benefits such as high sensitivity, specificity, and resolution.

In 2023, North America held a significant share of 40.8% in the molecular cytogenetics market and is predicted to witness substantial growth through 2032, backed by the advanced healthcare infrastructure, coupled with continuous technological advancements and high healthcare expenditure.

Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., BioView Ltd., Danaher Corporation, F. Hoffmann-La Roche Ltd., Illumina, Inc., MetaSystems, PerkinElmer, Inc., and Sysmex Corporation among others.